SHAREHOLDERS' EQUITY (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
| Schedule of Number of Reserved and Authorized Shares In Equity Incentive Plans |
| |
|
2025
|
|
| |
|
|
|
|
Share options exercised and outstanding
|
|
|
27,021,199
|
|
|
RSUs vested and outstanding
|
|
|
8,758,799
|
|
|
Ordinary shares available for issuance under the Share Option Plans
|
|
|
132,969
|
|
| |
|
|
|
|
|
Total reserved and authorized shares as of December 31, 2025
|
|
|
35,912,967
|
|
|
| Schedule of Stock Option Activity |
| |
|
Number of
options
|
|
|
Weighted-average
exercise price
|
|
|
Weighted- average remaining contractual term
(in years)
|
|
|
Aggregate
intrinsic value
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at January 1, 2025
|
|
|
1,639,897
|
|
|
$
|
22.56
|
|
|
|
2.39
|
|
|
$
|
2,928
|
|
|
Granted
|
|
|
120,000
|
|
|
|
23.58
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(39,005
|
)
|
|
|
23.63
|
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
(577,419
|
)
|
|
|
23.84
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(130,325
|
)
|
|
|
23.44
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2025
|
|
|
1,013,148
|
|
|
$
|
21.80
|
|
|
|
2.70
|
|
|
$
|
3,860
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at December 31, 2025
|
|
|
580,777
|
|
|
$
|
23.14
|
|
|
|
2.02
|
|
|
$
|
2,041
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest at December 31, 2025
|
|
|
1,006,518
|
|
|
$
|
21.80
|
|
|
|
2.69
|
|
|
$
|
3,843
|
|
|
| Schedule of Stock Options Outstanding by Exercise Price Range |
|
December 31, 2025
|
|
|
Outstanding
|
|
|
Exercisable
|
|
| |
|
|
|
|
|
Weighted-
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
average
|
|
|
Weighted-
|
|
|
|
|
|
Weighted-
|
|
|
Ranges of
|
|
|
|
|
|
remaining
|
|
|
average
|
|
|
|
|
|
average
|
|
|
exercise
|
|
|
Number of
|
|
|
contractual
|
|
|
exercise
|
|
|
Number of
|
|
|
exercise
|
|
|
price
|
|
|
options
|
|
|
life (years)
|
|
|
price
|
|
|
options
|
|
|
price
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
15.12-19.75
|
|
|
|
511,755
|
|
|
|
2.81
|
|
|
$
|
17.29
|
|
|
|
281,218
|
|
|
$
|
17.42
|
|
|
$
|
22.5-24.4
|
|
|
|
302,271
|
|
|
|
3.53
|
|
|
$
|
22.99
|
|
|
|
102,271
|
|
|
$
|
22.61
|
|
|
$
|
27.71-29.1
|
|
|
|
74,000
|
|
|
|
1.28
|
|
|
$
|
28.89
|
|
|
|
74,000
|
|
|
$
|
28.89
|
|
|
$
|
32.71-35.43
|
|
|
|
125,122
|
|
|
|
1.09
|
|
|
$
|
33.16
|
|
|
|
123,288
|
|
|
$
|
33.15
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
1,013,148
|
|
|
|
|
|
|
|
|
|
|
|
580,777
|
|
|
|
|
|
|
| Schedule of RSU Activity |
| |
|
Year ended
December 31,
|
|
| |
|
2025
|
|
| |
|
|
|
|
Outstanding at January 1, 2025
|
|
|
3,455,138
|
|
|
Granted
|
|
|
1,077,315
|
|
|
Vested
|
|
|
(1,012,142
|
)
|
|
Forfeited
|
|
|
(244,418
|
)
|
| |
|
|
|
|
|
Outstanding as of December 31, 2025
|
|
|
3,275,893
|
|
|
| Schedule of Stock-Based Compensation Expense |
| |
|
Year ended
December 31,
|
|
| |
|
2025
|
|
|
2024
|
|
|
2023
|
|
| |
|
|
|
|
|
|
|
|
|
|
Cost of revenues
|
|
$
|
574
|
|
|
$
|
366
|
|
|
$
|
515
|
|
|
Research and development, net
|
|
|
5,674
|
|
|
|
6,113
|
|
|
|
8,505
|
|
|
Sales and marketing
|
|
|
12,084
|
|
|
|
10,881
|
|
|
|
12,554
|
|
|
General and administrative
|
|
|
5,703
|
|
|
|
8,667
|
|
|
|
12,448
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
$
|
24,035
|
|
|
$
|
26,027
|
|
|
$
|
34,022
|
|
|